Intramuscular neridronate for the treatment of complex regional pain syndrome type 1: a randomized, double-blind, placebo-controlled study.
algodystrophy
bisphosphonates
complex regional pain syndrome type 1
neridronate
randomized clinical trial
Journal
Therapeutic advances in musculoskeletal disease
ISSN: 1759-720X
Titre abrégé: Ther Adv Musculoskelet Dis
Pays: England
ID NLM: 101517322
Informations de publication
Date de publication:
2021
2021
Historique:
received:
20
01
2021
accepted:
12
04
2021
entrez:
28
6
2021
pubmed:
29
6
2021
medline:
29
6
2021
Statut:
epublish
Résumé
Complex regional pain syndrome type-1 (CRPS-1) is a severely disabling painful disease challenging to treat. This multicenter, randomized, double-blind placebo-controlled trial examined the efficacy of intramuscular (i.m.) neridronate in CRPS-1 patients. A total of 78 patients diagnosed with CRPS-1 (aged 59.5 ± 10.3, 66.7% female) were randomly assigned to 25 mg (i.m.) neridronate ( After 30 days, VAS score decreased significantly to a greater extent in neridronate-treated patients In patients with acute CRPS-1, i.m. injections of 25 mg neridronate were associated with clinically relevant benefit compared with placebo controls. EU Clinical Trials Register: https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001156-28.
Sections du résumé
BACKGROUND
BACKGROUND
Complex regional pain syndrome type-1 (CRPS-1) is a severely disabling painful disease challenging to treat. This multicenter, randomized, double-blind placebo-controlled trial examined the efficacy of intramuscular (i.m.) neridronate in CRPS-1 patients.
METHODS
METHODS
A total of 78 patients diagnosed with CRPS-1 (aged 59.5 ± 10.3, 66.7% female) were randomly assigned to 25 mg (i.m.) neridronate (
RESULTS
RESULTS
After 30 days, VAS score decreased significantly to a greater extent in neridronate-treated patients
CONCLUSION
CONCLUSIONS
In patients with acute CRPS-1, i.m. injections of 25 mg neridronate were associated with clinically relevant benefit compared with placebo controls.
TRIAL REGISTRATION
BACKGROUND
EU Clinical Trials Register: https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001156-28.
Identifiants
pubmed: 34178124
doi: 10.1177/1759720X211014020
pii: 10.1177_1759720X211014020
pmc: PMC8202309
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1759720X211014020Informations de copyright
© The Author(s), 2021.
Déclaration de conflit d'intérêts
Conflict of interest statement: Massimo Varenna has received advisory board honoraria from UCB and Kyowa Kirin, consultancy fees from Amgen, and speaker fees from Eli-Lilly and Sandoz. Davide Gatti has received advisory board honoraria from Pfizer, consultancy fees from Abiogen and UCB, and speaker fees from Celgene, Eli-Lilly, and Neopharmed-Gentili. Giovanni Iolascon has received speaker fees from Eli-Lilly and UCB. Maurizio Rossini has received advisory board honoraria and consultancy fees from Abiogen, Celgene, Sanofi, Eli-Lilly, and UCB and speaker fees from Abiogen, Amgen, Abbvie, BMS, Celgene, Grunenthal, Eli-Lilly, MSD, Novartis, Pfizer, Sanofi, Sandoz, and UCB. Fabrizio Nannipieri is an employee of Abiogen Pharma S.p.A. All other authors have no conflict of interest to declare.
Références
Pain Med. 2017 Jun 1;18(6):1131-1138
pubmed: 27651505
J Rheumatol. 2000 Jun;27(6):1477-83
pubmed: 10852274
J Bone Miner Res. 2011 Mar;26(3):512-8
pubmed: 20814970
J Clin Epidemiol. 1998 Nov;51(11):1025-36
pubmed: 9817120
Pain Med. 2013 Feb;14(2):180-229
pubmed: 23331950
Clin J Pain. 2003 Sep-Oct;19(5):281-5
pubmed: 12966253
J Bone Miner Res. 1996 Oct;11(10):1482-91
pubmed: 8889848
Nat Rev Rheumatol. 2013 Apr;9(4):199-200
pubmed: 23358509
Acta Anaesthesiol Scand. 2015 Jul;59(6):685-97
pubmed: 25903457
J Hand Surg Br. 1998 Feb;23(1):20-3
pubmed: 9571473
PLoS One. 2017 Mar 16;12(3):e0173688
pubmed: 28301606
Pain Med. 2014 Sep;15(9):1575-89
pubmed: 25234478
Joint Bone Spine. 2017 Jul;84(4):393-399
pubmed: 28408275
Expert Opin Drug Metab Toxicol. 2009 Oct;5(10):1305-11
pubmed: 19761412
Endocr Rev. 1998 Feb;19(1):80-100
pubmed: 9494781
Pain Rep. 2017 Oct 05;2(6):e624
pubmed: 29392238
Anesth Analg. 2016 Oct;123(4):1033-45
pubmed: 27636578
Arthritis Rheum. 2004 Nov;50(11):3690-7
pubmed: 15529370
Pain Med. 2004 Sep;5(3):276-80
pubmed: 15367305
Pain. 1985 Aug;22(4):399-405
pubmed: 4047708
Nucl Med Biol. 2002 Apr;29(3):329-38
pubmed: 11929703
Ann Rheum Dis. 1997 Mar;56(3):201-4
pubmed: 9135227
Bone. 2006 May;38(5):617-27
pubmed: 16046206
Pain Med. 2007 May-Jun;8(4):326-31
pubmed: 17610454
Calcif Tissue Int. 1987 Dec;41(6):326-31
pubmed: 3124942
Rheumatol Int. 2018 Nov;38(11):1959-1962
pubmed: 30008128
Pain. 2003 May;103(1-2):199-207
pubmed: 12749974
Rheumatology (Oxford). 2014 Jun;53(6):965-7
pubmed: 24273023
Lancet. 1974 Nov 9;2(7889):1127-31
pubmed: 4139420
Bone. 2011 Oct;49(4):710-6
pubmed: 21807133
Pain. 2012 Jun;153(6):1187-1192
pubmed: 22386473
Rheumatology (Oxford). 2013 Mar;52(3):534-42
pubmed: 23204550
Pain. 2010 Aug;150(2):268-274
pubmed: 20493633